A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression.

In this sample of moderately to severely depressed outpatients, nefazodone therapy proved superior to placebo. Nefazodone therapy was also associated with fewer dropouts from adverse effects than was imipramine. In view of these efficacy findings as well as the promising side effect and safety profile of nefazodone, further research is warranted to evaluate its therapeutic potential in the treatment of depressive illness.

RCT Entities:   Population Interventions Outcomes